Database : MEDLINE
Search on : Nervous and System and Neoplasms [Words]
References found : 44982 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 4499 go to page                         

  1 / 44982 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29455234
[Au] Autor:Wang S; Wang X; Liu M; Bai O
[Ad] Address:Department of Hematology, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District, Changchun, 130021, Jilin, People's Republic of China.
[Ti] Title:Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
[So] Source:Ann Hematol;97(4):563-572, 2018 Apr.
[Is] ISSN:1432-0584
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy mainly affecting elderly patients. Most patients present with asymptomatic skin lesions as the first symptom and has a high frequency of bone marrow involvement. BPDCN is typically characterized by CD4+ and CD 56+ co-expression without common lymphoid or myeloid lineage markers. There is no consensus on the optimal therapeutic strategy for BPDCN. It is highly responsive to chemotherapy but the median event-free survival is very short. Allogeneic stem cell transplantation may improve the prognosis of BPDCN but the rate of relapse is still high. There are no specific targeted agents approved for patients with BPDCN, but advances in the understanding of the pathobiology of BPDCN and the results of early clinical studies have revealed novel targets and potentially effective agents. Novel targeted therapies may improve outcomes for patients with BPDCN in the future.
[Mh] MeSH terms primary: Antineoplastic Agents/therapeutic use
Dendritic Cells/drug effects
Drugs, Investigational/therapeutic use
Hematologic Neoplasms/drug therapy
[Mh] MeSH terms secundary: Animals
Antineoplastic Agents/pharmacology
Antineoplastic Combined Chemotherapy Protocols/pharmacology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Cell Line, Tumor
Central Nervous System Neoplasms/diagnosis
Central Nervous System Neoplasms/prevention & control
Central Nervous System Neoplasms/secondary
Dendritic Cells/pathology
Drugs, Investigational/pharmacology
Hematologic Neoplasms/diagnosis
Hematologic Neoplasms/pathology
Hematologic Neoplasms/surgery
Hematopoietic Stem Cell Transplantation/adverse effects
Humans
Prognosis
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (Drugs, Investigational)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180219
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-018-3259-z

  2 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29247857
[Au] Autor:Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
[Ad] Address:Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
[Ti] Title:A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
[So] Source:Eur J Med Chem;144:1-28, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:Glioblastoma multiforme (GBM) is the most common and deadliest of malignant brain tumors in adults. Disease development is associated with dysregulation of the cyclin D-CDK4/6-INK4-Rb pathway, resulting in increased proliferation; thus, CDK4/6 kinase inhibitors are promising candidates for GBM treatment. The recently developed CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, are effective in subcutaneous glioma models, but their blood-brain barrier (BBB) permeability is poor, limiting drug delivery to the central nervous system. Here, we designed and synthesized a series of novel CDK4/6 inhibitors with favorable BBB permeability for the treatment of GBM. Compound 11 exhibited a favorable pharmacological profile and significant penetration of the BBB with the K value of 4.10 and the K value of 0.23 in mice after an oral dose of 10 mg/kg. IC values for CDK4/cyclin D1 and CDK6/cyclin D3 were 3 nM and 1 nM, respectively. In vivo studies with an orthotopic xenograft mouse model of GBM showed that 11 had tumor growth inhibition values ranging from 62% to 99% for doses ranging from 3.125 to 50 mg/kg, and no significant body weight loss was observed. The increase in life span based on the median survival time of vehicle-treated animals in mice administered a dose of 50 mg/kg was significant at 162% (p < 0.0001). These results suggest that compound 11 is a promising candidate for further investigation as an effective drug for the treatment of GBM.
[Mh] MeSH terms primary: Brain Neoplasms/drug therapy
Cyclin-Dependent Kinase 4/antagonists & inhibitors
Cyclin-Dependent Kinase 6/antagonists & inhibitors
Drug Design
Glioblastoma/drug therapy
Protein Kinase Inhibitors/pharmacokinetics
Protein Kinase Inhibitors/therapeutic use
[Mh] MeSH terms secundary: Animals
Blood-Brain Barrier/metabolism
Blood-Brain Barrier/pathology
Brain Neoplasms/metabolism
Brain Neoplasms/pathology
Cell Line, Tumor
Cyclin-Dependent Kinase 4/metabolism
Cyclin-Dependent Kinase 6/metabolism
Dogs
Glioblastoma/metabolism
Glioblastoma/pathology
Humans
Madin Darby Canine Kidney Cells
Male
Mice
Protein Kinase Inhibitors/chemistry
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Protein Kinase Inhibitors); EC 2.7.11.22 (Cyclin-Dependent Kinase 4); EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:171217
[St] Status:MEDLINE

  3 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29521646
[Au] Autor:Velázquez Vega JE; Brat DJ
[Ad] Address:Department of Pathology and Laboratory Medicine, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.
[Ti] Title:Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
[So] Source:Adv Anat Pathol;, 2018 Mar 08.
[Is] ISSN:1533-4031
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Recent advances in molecular pathology have reshaped the practice of brain tumor diagnostics. The classification of gliomas has been restructured with the discovery of isocitrate dehydrogenase (IDH) 1/2 mutations in the vast majority of lower grade infiltrating gliomas and secondary glioblastomas (GBM), with IDH-mutant astrocytomas further characterized by TP53 and ATRX mutations. Whole-arm 1p/19q codeletion in conjunction with IDH mutations now define oligodendrogliomas, which are also enriched for CIC, FUBP1, PI3K, NOTCH1, and TERT-p mutations. IDH-wild-type (wt) infiltrating astrocytomas are mostly primary GBMs and are characterized by EGFR, PTEN, TP53, NF1, RB1, PDGFRA, and CDKN2A/B alterations, TERT-p mutations, and characteristic copy number alterations including gains of chromosome 7 and losses of 10. Other clinically and genetically distinct infiltrating astrocytomas include the aggressive H3K27M-mutant midline gliomas, and smaller subsets that occur in the setting of NF1 or have BRAF V600E mutations. Low-grade pediatric gliomas are both genetically and biologically distinct from their adult counterparts and often harbor a single driver event often involving BRAF, FGFR1, or MYB/MYBL1 genes. Large scale genomic and epigenomic analyses have identified distinct subgroups of ependymomas tightly linked to tumor location and clinical behavior. The diagnosis of embryonal neoplasms also integrates molecular testing: (I) 4 molecularly defined, biologically distinct subtypes of medulloblastomas are now recognized; (II) 3 histologic entities have now been reclassified under a diagnosis of "embryonal tumor with multilayered rosettes (ETMR), C19MC-altered"; and (III) atypical teratoid/rhabdoid tumors (AT/RT) now require SMARCB1 (INI1) or SMARCA4 (BRG1) alterations for their diagnosis. We discuss the practical use of contemporary biomarkers for an integrative diagnosis of central nervous system neoplasia.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1097/PAP.0000000000000186

  4 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29507614
[Au] Autor:Gauberti M; Fournier AP; Docagne F; Vivien D; Martinez de Lizarrondo S
[Ad] Address:Normandie Univ, UNICAEN, INSERM, INSERM UMR-S U1237, Physiopathology and Imaging for Neurological Disorders (PhIND), Cyceron, 14000 Caen, France.
[Ti] Title:Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System.
[So] Source:Theranostics;8(5):1195-1212, 2018.
[Is] ISSN:1838-7640
[Cp] Country of publication:Australia
[La] Language:eng
[Ab] Abstract:Endothelial cells of the central nervous system over-express surface proteins during neurological disorders, either as a cause, or a consequence, of the disease. Since the cerebral vasculature is easily accessible by large contrast-carrying particles, it constitutes a target of choice for molecular magnetic resonance imaging (MRI). In this review, we highlight the most recent advances in molecular MRI of brain endothelial activation and focus on the development of micro-sized particles of iron oxide (MPIO) targeting adhesion molecules including intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), P-Selectin and E-Selectin. We also discuss the perspectives and challenges for the clinical application of this technology in neurovascular disorders (ischemic stroke, intracranial hemorrhage, subarachnoid hemorrhage, diabetes mellitus), neuroinflammatory disorders (multiple sclerosis, brain infectious diseases, sepsis), neurodegenerative disorders (Alzheimer's disease, vascular dementia, aging) and brain cancers (primitive neoplasms, metastasis).
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review
[do] DOI:10.7150/thno.22662

  5 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29382830
[Au] Autor:Aramillo Irizar P; Schäuble S; Esser D; Groth M; Frahm C; Priebe S; Baumgart M; Hartmann N; Marthandan S; Menzel U; Müller J; Schmidt S; Ast V; Caliebe A; König R; Krawczak M; Ristow M; Schuster S; Cellerino A; Diekmann S; Englert C; Hemmerich P; Sühnel J; Guthke R; Witte OW; Platzer M; Ruppin E; Kaleta C
[Ad] Address:Research Group Medical Systems Biology, Institute of Experimental Medicine, Christian-Albrechts-University Kiel, D-24105, Kiel, Germany.
[Ti] Title:Transcriptomic alterations during ageing reflect the shift from cancer to degenerative diseases in the elderly.
[So] Source:Nat Commun;9(1):327, 2018 01 30.
[Is] ISSN:2041-1723
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Disease epidemiology during ageing shows a transition from cancer to degenerative chronic disorders as dominant contributors to mortality in the old. Nevertheless, it has remained unclear to what extent molecular signatures of ageing reflect this phenomenon. Here we report on the identification of a conserved transcriptomic signature of ageing based on gene expression data from four vertebrate species across four tissues. We find that ageing-associated transcriptomic changes follow trajectories similar to the transcriptional alterations observed in degenerative ageing diseases but are in opposite direction to the transcriptomic alterations observed in cancer. We confirm the existence of a similar antagonism on the genomic level, where a majority of shared risk alleles which increase the risk of cancer decrease the risk of chronic degenerative disorders and vice versa. These results reveal a fundamental trade-off between cancer and degenerative ageing diseases that sheds light on the pronounced shift in their epidemiology during ageing.
[Mh] MeSH terms primary: Aging/genetics
Cardiovascular Diseases/genetics
Diabetes Mellitus/genetics
Neoplasms/genetics
Neurodegenerative Diseases/genetics
Transcriptome
[Mh] MeSH terms secundary: Adolescent
Adult
Aged
Aged, 80 and over
Aging/metabolism
Aging/pathology
Animals
Brain/growth & development
Brain/metabolism
Cardiovascular Diseases/blood
Cardiovascular Diseases/pathology
Child
Child, Preschool
Chronic Disease
Diabetes Mellitus/blood
Diabetes Mellitus/pathology
Fundulidae/genetics
Fundulidae/growth & development
Fundulidae/metabolism
Gene Ontology
Genome, Human
Humans
Infant
Liver/growth & development
Liver/metabolism
Mice
Middle Aged
Molecular Sequence Annotation
Neoplasms/metabolism
Neoplasms/pathology
Neurodegenerative Diseases/blood
Neurodegenerative Diseases/pathology
Skin/growth & development
Skin/metabolism
Zebrafish/genetics
Zebrafish/growth & development
Zebrafish/metabolism
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:180201
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02395-2

  6 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28954297
[Au] Autor:Bandos H; Melnikow J; Rivera DR; Swain SM; Sturtz K; Fehrenbacher L; Wade JL; Brufsky AM; Julian TB; Margolese RG; McCarron EC; Ganz PA
[Ad] Address:NRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at
[Ti] Title:Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL). Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer. The AC→T group had a higher cumulative dose of T. PN was one of the symptoms assessed in a QOL substudy. Statistical methods included simple and mixed ordinal logistic regression and general linear models. All statistical tests were two-sided. Results: Of 1512 patients, 41.9% reported PN two years after treatment initiation. Treatment with AT and ACT was associated with less severe long-term PN compared with AC→T (odds ratio [OR] = 0.45, 95% confidence interval [CI] = 0.35 to 0.58; OR = 0.59, 95% CI = 0.46 to 0.75). Preexisting PN, older age, obesity, mastectomy, and greater number of positive nodes were also associated with higher risk of long-term PN. Patients who reported worse PN symptoms at 24 months had statistically significantly worse QOL (Ptrend < .001). Conclusions: The administration of docetaxel is associated with long-term PN. The lower rate of long-term PN in AT and ACT patients might be an important consideration in supporting choosing these therapies for individuals with preexisting neuropathic symptoms or other risk factors for neuropathy.
[Mh] MeSH terms primary: Antineoplastic Combined Chemotherapy Protocols/adverse effects
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Breast Neoplasms/drug therapy
Peripheral Nervous System Diseases/chemically induced
[Mh] MeSH terms secundary: Chemotherapy, Adjuvant
Cyclophosphamide/adverse effects
Doxorubicin/administration & dosage
Doxorubicin/adverse effects
Drug Administration Schedule
Female
Humans
Middle Aged
Quality of Life
Taxoids/administration & dosage
Taxoids/adverse effects
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Name of substance:0 (Taxoids); 15H5577CQD (docetaxel); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide)
[Em] Entry month:1710
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx162

  7 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28954296
[Au] Autor:Rivera DR; Ganz PA; Weyrich MS; Bandos H; Melnikow J
[Ad] Address:Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; Schools of Medicine and Public Health and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA; Center for Healthcare Policy and Research, University of California Davi
[Ti] Title:Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Breast cancer is the most common cancer among women worldwide, and survival rates are increasing. Chemotherapy-associated peripheral neuropathy (PN) is clinically important because of effects on quality of life (QOL) and potential effects on dose limitations. This adverse drug reaction is associated with certain classes of chemotherapy and commonly presents as peripheral sensory neuropathy whose natural course is largely unknown. The literature was reviewed to determine the frequency and characteristics of PN associated with adjuvant chemotherapy in early-stage breast cancer (ESBC) to explore the potential impact on long-term (one or more years after diagnosis) health outcomes and QOL. MEDLINE, PubMed, Embase, and the Cochrane Library were searched for relevant English-language randomized controlled trials, systematic reviews, meta-analyses, and case-control and cohort studies published between January 1990 and July 1996. Included studies were limited to current adjuvant regimens (eg, anthracyclines, taxanes, cyclophosphamide, platinum compounds). Two investigators independently reviewed abstracts, full-text articles, and extracted data from fair- and good-quality studies. Discrepancies in quality assessment and data extraction were resolved by consensus. We identified 364 articles; 60 were eligible for full-text review. Only five reports of four studies provided data beyond one year post-treatment initiation. Studies used different measures to assess PN. Neuropathic symptoms persisted in 11.0% to more than 80% of participants at one to three years following treatment. There is a paucity of data describing persistent PN in ESBC patients. Consistent use of validated measures and well-conducted randomized clinical trials or observational studies are needed to evaluate the incidence, persistence, and QOL associated with the long-term effects of PN.
[Mh] MeSH terms primary: Antineoplastic Agents/adverse effects
Breast Neoplasms/drug therapy
Breast Neoplasms/pathology
Peripheral Nervous System Diseases/chemically induced
[Mh] MeSH terms secundary: Antineoplastic Agents/therapeutic use
Female
Humans
Neoplasm Staging
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Antineoplastic Agents)
[Em] Entry month:1710
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx140

  8 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28746860
[Au] Autor:Rogawski DS; Vitanza NA; Gauthier AC; Ramaswamy V; Koschmann C
[Ad] Address:Department of Pediatrics, University of Michigan School of Medicine, Ann Arbor, Mich.
[Ti] Title:Integrating RNA sequencing into neuro-oncology practice.
[So] Source:Transl Res;189:93-104, 2017 Nov.
[Is] ISSN:1878-1810
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Malignant tumors of the central nervous system (CNS) cause substantial morbidity and mortality, yet efforts to optimize chemo- and radiotherapy have largely failed to improve dismal prognoses. Over the past decade, RNA sequencing (RNA-seq) has emerged as a powerful tool to comprehensively characterize the transcriptome of CNS tumor cells in one high-throughput step, leading to improved understanding of CNS tumor biology and suggesting new routes for targeted therapies. RNA-seq has been instrumental in improving the diagnostic classification of brain tumors, characterizing oncogenic fusion genes, and shedding light on intratumor heterogeneity. Currently, RNA-seq is beginning to be incorporated into regular neuro-oncology practice in the form of precision neuro-oncology programs, which use information from tumor sequencing to guide implementation of personalized targeted therapies. These programs show great promise in improving patient outcomes for tumors where single agent trials have been ineffective. As RNA-seq is a relatively new technique, many further applications yielding new advances in CNS tumor research and management are expected in the coming years.
[Mh] MeSH terms primary: Medical Oncology
Nervous System Neoplasms/genetics
Sequence Analysis, RNA/methods
[Mh] MeSH terms secundary: Gene Expression Regulation, Neoplastic
Humans
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1711
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170727
[St] Status:MEDLINE

  9 / 44982 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29480846
[Au] Autor:Cai J; Li W; Du J; Xu N; Gao P; Zhou J; Li X
[Ad] Address:Department of Radiology, Beijing Tiantan Hospital affiliated to Capital Medical University.
[Ti] Title:Supratentorial intracerebral cerebellar liponeurocytoma: A case report and literature review.
[So] Source:Medicine (Baltimore);97(2):e9556, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Cerebellar liponeurocytoma is a rare tumor of the central nervous system (CNS) characterized by low proliferation but high likelihood of recurrence. Because of its rarity and the paucity of systematic follow-up, the biological behaviors and clinical features of this tumor are still poorly understood. We herein reported a case of cerebellar liponeurocytoma originating in the cerebral hemisphere. PATIENT CONCERNS: A 11-year-old male with intermittent headache, nausea, and vomiting. The first computed tomography revealed a large mass in the right cerebral hemisphere. He was transferred to our institution for neurosurgical treatment. DIAGNOSIS: Magnetic resonance imaging showed a large cystic-solid mass in the right frontal lobe with obvious contrast enhancement. Histopathological examinations showed sheets of isomorphic small neoplastic cells with clear cytoplasm and focal lipomatous differentiation. On immunohistochemistry, tumor cells were positive for synaptophysin, microtubule-associated protein 2, and neuronal nuclei antigen. INTERVENTIONS: The patient was performed a right fronto-parietal craniotomy, and gross total resection of the tumor was achieved without adjuvant therapy. OUTCOMES: No clinical or neuroradiological evidence of recurrence or residual of the tumor was found 6 years and 2 months after initial surgery. LESSONS: Cerebellar liponeurocytoma developing in supratentorial cerebral hemisphere was first reported in the present study. The radiological and histopathological features may be useful in differentiating this rare tumor from other tumors at similar locations. A change in the nomenclature of cerebellar liponeurocytomas should be considered in future World Health Organization (WHO) classifications.
[Mh] MeSH terms primary: Cerebellar Neoplasms/diagnostic imaging
Cerebellar Neoplasms/surgery
Neurocytoma/diagnostic imaging
Neurocytoma/surgery
Supratentorial Neoplasms/diagnostic imaging
Supratentorial Neoplasms/surgery
[Mh] MeSH terms secundary: Cerebellar Neoplasms/pathology
Child
Diagnosis, Differential
Humans
Male
Neurocytoma/pathology
Supratentorial Neoplasms/pathology
Terminology as Topic
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009556

  10 / 44982 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28451716
[Au] Autor:Mayer C; Hattingen E; Schild H; Bootz F; Schröck A
[Ad] Address:Klinik für Radiologie, Universität Bonn, Bonn, Deutschland.
[Ti] Title:Interventionelle Radiologie im Kopf-Hals-Bereich. [Interventional radiology in the head and neck region].
[So] Source:HNO;65(6):482-489, 2017 Jun.
[Is] ISSN:1433-0458
[Cp] Country of publication:Germany
[La] Language:ger
[Ab] Abstract:In interventional neuroradiology, endovascular embolization represents an important and helpful tool in the treatment of multiple head and neck diseases. These interventional procedures may be performed with curative intent, to reduce the surgical risk within a multimodal treatment concept, or to improve or at least maintain a good quality of life within a palliative therapy concept. In addition to a good understanding of disease pathology, knowledge of vascular anatomy, including collateral vessels and dangerous extracranial-intracranial anastomoses, is essential for successful treatment, as is implementation of an established technique using appropriate material. Indications for endovascular embolization are i. otherwise unmanageable bleeding (caused by e. g., trauma, vascular malformation, or tumor), ii. reduction of perioperative bleeding by preoperative embolization in case of a hypervascularized tumor, iii. selective induction of tumor necrosis by palliative embolization to enhance local tumor control. Major complications such as stroke, loss of vision, and cranial nerve palsy are mostly due to a lack of preinterventional evaluation. Regarding neurological deficits, interventions within the supply region of the external carotid artery have a complication rate below 1%.
[Mh] MeSH terms primary: Central Nervous System Vascular Malformations/diagnostic imaging
Central Nervous System Vascular Malformations/therapy
Embolization, Therapeutic/methods
Head and Neck Neoplasms/diagnostic imaging
Head and Neck Neoplasms/therapy
Hemostatics/therapeutic use
Radiography, Interventional/methods
[Mh] MeSH terms secundary: Evidence-Based Medicine
Head/blood supply
Head/diagnostic imaging
Humans
Neck/blood supply
Neck/diagnostic imaging
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Hemostatics)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:IM
[Da] Date of entry for processing:170429
[St] Status:MEDLINE
[do] DOI:10.1007/s00106-017-0354-8


page 1 of 4499 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information